Get the Stockscreener App
377.36
1.48%
5.8575
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $377.36, with a volume of 1.09M.
It is up +1.48% in the last 24 hours and up +7.27% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$371.50
Open:
$372.725
24h Volume:
1.09M
Relative Volume:
0.42
Market Cap:
$203.67B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
26.24
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+2.92%
1M Performance:
+7.27%
6M Performance:
+9.35%
1Y Performance:
+22.18%
1-Day Range:
$372.16
$379.41
1-Week Range:
$359.21
$379.41
52-Week Range:
$269.77
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
377.37 | 200.50B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,201.79 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
262.98 | 624.12B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
259.40 | 453.92B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
131.32 | 322.26B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.57 | 296.78B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen hands in data package in hopes of FDA hearing for Tavneos defense - Fierce Pharma
Amgen submits new data to challenge FDA's proposal to withdraw Tavneos - Reuters
Amgen stock trades steady as recent earnings and pipeline updates shape investor focus - Ad-hoc-news.de
Amgen Says Strongly Disagrees With FDA'S Proposal To Withdraw Tavneos From The U.S. Market - TradingView
Amgen Inc. $AMGN Shares Sold by Oak Associates Ltd. OH - MarketBeat
Public Employees Retirement System of Ohio Grows Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by Sei Investments Co. - MarketBeat
Compound Planning Inc. Buys 7,818 Shares of Amgen Inc. $AMGN - MarketBeat
Dickmeyer Boyce Financial Management Inc. Acquires Shares of 2,888 Amgen Inc. $AMGN - MarketBeat
Amgen stock trades steady as biosimilar growth offsets mixed Q1 2026 trends - Ad-hoc-news.de
Amgen Inc. $AMGN Shares Acquired by Cetera Investment Advisers - MarketBeat
Bank of Nova Scotia Has $110.56 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen stock trades steady as recent earnings and pipeline progress shape investor view - Ad-hoc-news.de
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest - Yahoo Finance
What Amgen (AMGN)'s Blocked Colorado Enbrel Price Cap Means For Shareholders - simplywall.st
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts - Yahoo Finance Singapore
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026? - The Motley Fool
Amgen stock rises on earnings and pipeline progress - Ad-hoc-news.de
Amgen Inc (NASDAQ:AMGN) Shows Technical Strength and Breakout Setup - ChartMill
Amgen stock edges higher as oncology pipeline and restructuring savings shape outlook - Ad-hoc-news.de
Amgen Inc. $AMGN Shares Acquired by NewEdge Wealth LLC - MarketBeat
Amgen Inc. $AMGN Shares Bought by First Trust Advisors LP - MarketBeat
Amgen stock holds near record levels as earnings and guidance frame the outlook - Ad-hoc-news.de
AMGN stock rises as 2025 revenue reaches $33.4 billion - Ad-hoc-news.de
Amgen stock trades steady as oncology and obesity pipeline shapes long term growth - Ad-hoc-news.de
Amgen (AMGN) Settles Lawsuit for $74 Million Over Tax Disclosure Delay - GuruFocus
Working capital per share of Amgen Inc. – BCS:AMGN1 - TradingView
Amgen stock trades steadily as recent results and pipeline shape investor sentiment - Ad-hoc-news.de
PNC Financial Services Group Inc. Buys 24,577 Shares of Amgen Inc. $AMGN - MarketBeat
Danica Pension Livsforsikringsaktieselskab Invests $12.14 Million in Amgen Inc. $AMGN - MarketBeat
ABN Amro Investment Solutions Cuts Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen stock holds steady as Repatha growth offsets biosimilar pressure - Ad-hoc-news.de
Amgen (AMGN) Clears An Enbrel Overhang, Is The Stock Fully Priced? - Yahoo! Finance Canada
Amgen (AMGN) Stock Looks Reasonable On Earnings While Cash Flow Stays Strong - simplywall.st
ETFs Investing in Amgen Inc. Stocks - TradingView
More Than Dry Eyes: The Many Faces of Sjögren’s Disease - Amgen
Amgen To Pay $74M To End Investor Suit Over $10.7B Tax Bill - Law360
$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today - Benzinga
Amgen agrees to $74M settlement to resolve investor lawsuit over potential $10.7B tax bill - Fierce Pharma
Amgen Settles Investor Suit Over Tax Liability for $74 Million - Bloomberg Law News
Amgen stock trades steady as obesity pipeline and recent earnings shape outlook - Ad-hoc-news.de
Amgen settles shareholder lawsuit claiming it hid $10.7 billion tax bill - Reuters
Amgen stock holds near its yearly range as investors await the next earnings date. - Ad-hoc-news.de
Commerzbank Aktiengesellschaft FI Raises Position in Amgen Inc. $AMGN - MarketBeat
Andra AP fonden Has $17.72 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen stock holds steady on latest earnings context - Ad-hoc-news.de
Amgen stock trades steadily as oncology pipeline and recent earnings shape sentiment - Ad-hoc-news.de
Amgen stock trades steady as investors weigh recent revenue growth and obesity pipeline progress - Ad-hoc-news.de
Amgen stock trades steadily as cardiovascular drug data and oncology pipeline shape outlook - Ad-hoc-news.de
Amgen Earnings Preview: What to Expect - Barchart.com
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):